Potentially modifiable predictors of mortality in patients treated with long-term oxygen therapy  by Lima, Daniela F. et al.
Respiratory Medicine (2011) 105, 470e476ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedPotentially modifiable predictors of mortality in
patients treated with long-term oxygen therapy*Daniela F. Lima a,*, Karina Dela Coleta a, Suzana E. Tanni a,
Liciana V.A. Silveira b, Ilda Godoy c, Irma Godoy aaDepartment of Internal Medicine, Pulmonology Division, Botucatu Medical School, UNESP e Sa˜o Paulo State University,
Distrito de Rubia˜o Ju´nior, s/n. Botucatu, CEP 18618-000, SP, Brazil
bDepartment of Biostatistics, Biosciences Institute, UNESP e Sa˜o Paulo State University, Distrito de Rubia˜o Ju´nior,
s/n, Botucatu, CEP 18618-000, SP, Brazil
cDepartment of Nursing, Botucatu Medical School, UNESP e Sa˜o Paulo State University, Distrito de Rubia˜o Ju´nior,
s/n, Botucatu, CEP 18618-000, SP, Brazil
Received 25 May 2010; accepted 26 August 2010
Available online 16 September 2010KEYWORDS
Chronic respiratory
failure;
Long-term oxygen
therapy;
Predictors of mortality;
COPD;
Hemoglobin;
Hematocrit* This study received financial suppo
Superior) [grant no. 133880/2007-9].
* Corresponding author. Rua 13 de m
14 3882 2238.
E-mail address: dani_flima@hotma
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.08.012Summary
Introduction: Anemia is considered a systemic manifestation of Chronic Obstructive Pulmonary
Disease (COPD); however, few studies have described its influence on chronic respiratory
failure (CRF) prognosis. We aimed to test the hypotheses that anemia negatively influences
survival and also to identify the cut-off points of hematocrit (Htc) and hemoglobin (Hb) asso-
ciated with higher mortality in CRF patients using long-term oxygen therapy (LTOT).
Methods: One-hundred forty two patients with CRF in use of LTOT were evaluated at baseline
and followed for three years or until death. Baseline assessment included identification, diag-
nosis, body composition, dyspnea, health status (HS), spirometry, arterial blood gases, Hb and
Htc. Univariate and Cox proportional hazard models were used to evaluate predictors of
mortality. We performed ROC curve to identify the best cut-off point of the variables related
to survival to construct the KaplaneMeier curves.
Results: Eight-three patients (58%) died after three years. Baseline values of Hb and Htc were
significantly lower in the non-survivors group and both, Htc (HR, 0.96; 95%CI 0.91e0.99;
pZ 0.04), Hb (HR, 0.86; 95%CI 0.76e0.98; pZ 0.02) were selected as predictors of mortality
after three years. The cut-off points determined were: the value of HB is < 11g/dl (sensitivity
95% specificity 85%), Htc  33% (sensitivity 97% specificity 89%). Other prognostic factors were:
male gender, low PaCO2 and SpO2, higher dyspnea perception and impairment of HS.rt in the form of a research grant from CAPES (Coordenac¸a˜o de Aperfeic¸oamento de Pessoal de Nı´vel
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Predictors of mortality in LTOT 471Conclusions: Our study shows that anemia is a predictor of mortality in patients with CRF under
LTOT treatment. Although anemia is potentially modifiable, the effects of raising hemoglobin
on mortality remain undetermined.
ª 2010 Elsevier Ltd. All rights reserved.157 patients 
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The advanced stage of lung, heart and systemic diseases
may be associated with the development of chronic respi-
ratory failure (CRF). The treatment of this complication
includes the use of long-term oxygen therapy (LTOT);
a single treatment that has proven to be effective in
increasing survival in hypoxemic patients with chronic
obstructive pulmonary disease (COPD).1,2 LTOT has also
been associated with significant improvement in health
status (HS), reduction of exacerbations and hospitalization
due to COPD.3 Approximately 67.8e81.6% of patients under
LTOT have COPD4,5; however, patients with chronic
hypoxemia from any cause can be included in treatment.6
Age, gender and concomitant malignancy are non-
modifiable predictors for mortality in patients with
LTOT.7e14 Some potentially modifiable predictors of
mortality in these patients have also been identified such as
active smoking, malnutrition, dyspnea, airflow obstruction,
hypoxemia, hypercapnia and pulmonary hypertension.
Anemia is recognized as comorbidity in many chronic
inflammatory diseases including COPD.16 Hemoglobin is
a major carrier of oxygen and two previous studies showed
influence of anemia on survival in patients with severe
airflow obstruction15 and with chronic hypoxemia.12
However, the values of hemoglobin (Hb) and hematocrit
(Htc) associated with higher mortality have not been
established. Anemia is a potentially modifiable prognostic
factor and we will test the hypothesis that lower values of
Hb and/or Htc negatively influence survival and intend to
identify the cut-off points associated with higher mortality
in patients using LTOT.15 patients were 
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incomplete data 
142 patients 
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Figure 1 Diagram showing the flow of participants of the
study.Methods
Individuals
We evaluated 168 consecutive patients referred to the
LTOT program of a tertiary-care university hospital (Botu-
catu Medical School, Botucatu, Brazil). Eleven patients did
not fulfill the criteria for LTOT according to the Brazilian
guidelines for COPD patients17; therefore, 157 patients
were enrolled in the study and monitored for three years or
until death. However, data were incomplete in 15 patients,
so this research will present the results for 142 patients
(Fig. 1). In 95 patients (67%) the principal diagnosis was
COPD. Other diagnoses in order of prevalence were: inter-
stitial lung disease in 13 patients (9%), pulmonary vascular
disease in 9 (6%); bronchiectasis in 6 (4%), obstructive sleep
apnea in 4 (3%), cardiac diseases in 4 (3%) and 11 patients
(8%) had miscellaneous diagnostics. Patients with CRF of
any etiology that meet the criteria for LTOT recommended
for patients with COPD and chronic hypoxemia17 wereincluded in the study. Additional inclusion criteria were as
following: 1) clinically stable condition (i.e., no changes in
medication dosage or frequency and no exacerbations of
disease or hospital admissions in the preceding 6 weeks); 2)
use of LTOT for at least 3 months (to avoid inclusion of
patients with temporary oxygen supplementation). All
patients were optimized in terms of standard medical
therapy according to guidelines for the primary diagnosis.
Participants were aware of the proposed study procedures
and freely gave written informed consent. All procedures
were approved by the Research Ethics Committee of the
Botucatu Medical School University Hospital.
Assessment procedures
The initial assessment included the following data: personal
identification (age, gender, primary diagnosis, comorbidity
conditions and smoking history), maintenance medications,
body composition measurements, handgrip strength, spirom-
etry, arterial blood gases and blood counts (Hb and Htc). We
also evaluated dyspnea sensation and health status. The
patientswere followedwith regular appointments in the LTOT
clinic every three months during the first year and thereafter
every six months. In those appointments the adherence to
treatment (flow and number of hours of oxygen prescribed)
and the number of exacerbations and hospitalizations in the
472 D.F. Lima et al.period were investigated. Family or patients that missed an
appointment were contacted and in case of death, the cause
was investigated.
Smoking history was determined based on the number of
pack-years.18 We determined values of the forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC) based on
the flowevolume curve obtained using a spirometer (Medical
Graphics Corporation; St. Paul; MN, USA), before and 20 min
after inhalation of a beta 2-agonist (fenoterol 400 mg)
according to the criteria set by the American Thoracic
Society.19 Values of FEV1 are expressed in liters, in percent-
ages of FVC and as percentages of reference values.20 For
partial pressure of oxygen (PaO2) and partial pressure of
carbon dioxide (PaCO2) measurements, arterial blood was
drawn from the radial artery under standard anaerobic
conditions, while the patient was at rest and breathing room
air (Stat Profile 5 Plus; Nova Biomedical; Waltham, MA, USA).
Pulse oximetry (SpO2) was assessed using a portable Onyx
oximeter (Model 9500 Oximeter; Nonin Medical Inc.; Minne-
apolis, MN, USA). Hematological tests were performed
according to the criteria and using the methods for con-
ducting the routine examination of the Technical Section of
Laboratory and Clinical Analysis of Botucatu Medical School.
The values considered as references for anemia were: for
women (Hb< 12 g/dl or Htc< 35%) and men (Hb< 13 g/dl or
Htc < 40%).21 Body weight and height were measured. Body
mass index (BMIZweight in kg/height inm2)was calculated.
Body composition was evaluated using a bioelectrical
impedance analyzer (BIA 101A; RJL systems; Detroit, MI,
USA). Resistance was measured on the right side of the body
in the supine position, in accordance with the ESPEN guide-
lines.22 Fat-free mass (FFM) was estimated (in kg) using
a group-specific regression equation developed by Schols
et al. and the FFM index (FFMI) was also calculated
(expressed as FFM/height2).23 The arm muscle strength was
estimated based on handgrip strength of the dominant hand
(HGS dh) and non-dominant hand (HGS ndh), as measured
using a dynamometer (TEC-60; Technical Products; Clifton,
NJ, USA).24 Comorbidity was quantified according to the
Charlson comorbidity index (CCI).25 A translated version of
the St.George’sRespiratoryQuestionnaire (SGRQ), validated
for use in Brazil, was used to evaluate health status (HS).26
A similarly Brazilian modified version of the baseline dysp-
nea index (BDI), developed by Mahler,27 was used to deter-
mine the degree of dyspnea. The total BDI score ranges from
0 to 12, lower values of BDI representing worst dyspnea.
Oxygen treatment
During the initial assessment the titration was performed
and the prescription of oxygen made. Oxygen therapy was
prescribed for at least 18 h/day, using nasal prongs. The
flow rate necessary to obtain an SpO2  90% was deter-
mined in the LTOT clinic. Guidance was given to patients
and their families on the proper use and handling of the
oxygen concentrator. The oxygen equipment was provided
by the supplier, which also provided in-home technical
service to patients. Patients who were active smokers were
strongly advised to stop smoking and conducted for treat-
ment. The LTOT compliance data were evaluated by self-
reporting obtained from patients and their caregivers and
characterized as appropriate by investigator if the usereported was in compliance with the prescription. Portable
oxygen was not provided.
Statistical analysis
We used the statistical package Sigma Stat 3.2 (Inc., Chi-
cago, IL, USA) and SAS for Windows 9.1.3 (SAS Institute Inc.,
Cary, NC, USA). The descriptive analysis of quantitative
variables was made using t-Student for variables with
normal distribution and the ManneWhitney (non parametric
test) test for variables with non-normal distribution. The
study of association between the qualitative variables and
the death was performed using Chi-square or Fischer’s
exact test. The colinearity was avoided by exclusion of one
of the variables for what the correlation between them was
known. For analysis of each variable with the response
(time of life) the KaplaneMeier estimator (categorized
variables) or Cox model (continuous variables) were
applied. Independent variables associated with mortality
(presenting a p < 0.20) in the univariate analysis were then
incorporated into a forward stepwise multiple analysis
likewise based on the Cox proportional model. We per-
formed ROC curve to identify the points for the variables
representing the best sensibility and sensitivity in sepa-
rating between survivors and non-survivors during the
follow-up period. These cut-off points were applied to
construct the KaplaneMeier curves to show the difference
in survival by selected risk factors: BDI, SpO2, Hb and Htc.
Differences between survival curves were assessed using
log-rank test. All findings in this study were discussed at the
level of 5% significance.
Results
One hundred forty two patients (74 males and 68 females)
were followed for three years of study or until death
(Fig. 1). The measurements included in the statistical
analysis were those obtained in initial assessment. At
baseline, the mean age was 64.6  12.9 years; 67% of
patients presented COPD and 9% had interstitial lung disease
(ILD); 83 (58%) died in the period of three years: 37 (26%)
during the first year of follow-up, 23 (16%) in the second year
and 23 (16%) in the third year. The main causes of deaths
were respiratory (53%) and cardiovascular diseases (13%).
The baseline characteristics of all patients and compar-
ison between the groups of survivors and non-survivors are
presented in Table 1. TheHb andHtcwere significantly lower
in the non-survivors group. The sensation of dyspnea and the
impairment of health status were more intense in patients
who died during follow-up. There were not additional
significant differences between survivors and non-survivors,
however non-survivors were more likely to be males, older,
and to have lower mean values of PaCO2. Six non-survivors
and 10 survivors were active smokers (pZ 0.21).
The prevalence of different causes of chronic hypoxemia
was similar between survivors and non-survivors (pZ 0.53).
However, patients with ILD showed higher risk of death
when compared with COPD patients (HR Z 1.54, 95%
CI Z 1.16e2.08, p Z 0.04). Patients were using more than
one class of drugs in the management of their diseases with
no difference between survivors and non-survivors group.
Table 1 Baseline characteristics of the patients on LTOT according to the survival after 3-years of follow-up.
Variables Overall n Z 142 Non-survivors n Z 83 Survivors n Z 59 p value
Gender (M/F) 74/68 49/34 25/34 0.07
Age (years) 64.6  12.9 66.2  13.8 62.4  11.8 0.08
Smoking (pack-years) 51.9  39.4 53.8  41.2 49.5  37.2 0.56
Hemoglobin (g/dl) 14.9  2.6 14.4  2.6 15.5  2.5 0.01
Hematocrit (%) 47.2  8.4 45.8  8.6 49.1  7.9 0.02
FVC (%) 71.8  22.7 70.2  23.2 73.9  22.1 0.27
FEV1 (%) 50.1  25.4 50.6  27.1 49.4  23.5 0.91
FEV1/FVC (%) 55.1  17.3 56.2  18.4 53.7  15.8 0.51
PaO2 (mmHg) 53.1  11.8 53.1  13.4 53.3  8.9 0.90
PaCO2 (mmHg) 44.1  9.6 42.9  10.3 45.8  8.2 0.09
SpO2 (%) 84.4  8.6 83.0  10.1 86.3  5.7 0.11
CCI 4.0 (3.0e5.0) 4.0 (3.0e5.0) 4.0 (3.0e5.0) 0.15
BMI (kg/m2) 24.7  6.5 24.1  6.7 25.6  6.3 0.18
FFMI (kg/m2) 16.2  3.0 15.9  2.6 16.7  3.4 0.20
HGS dh (kgf) 25.3  11.1 24.5  11.2 26.6  10.9 0.30
HGS ndh (kgf) 23.4  11.4 22.7  11.7 24.3  10.9 0.39
Exacerbation (no/years) 0.5 (0.0e1.3) 0.3 (0.0e1.7) 0.7 (0.3e1.2) 0.76
BDI 3.5  2.9 2.8  2.6 4.5  3.1 < 0.001
SGRQ
Symptoms (%) 64.6  23.7 66.5  22.6 62.0  25.1 0.27
Activities (%) 72.1  19.0 75.2  17.3 67.7  20.5 0.03
Impact (%) 48.2  19.5 52.0  19.2 43.0  18.9 0.007
Total (%) 58.2  17.5 61.5  16.9 53.7  17.6 0.01
Test t-student or ManneWhitney was used. The data are presented as mean  SD or median (quartile 1-quartile 3). M/F, male/female;
FVC, forced vital capacity; FEV1, Forced expiratory volume in 1 s; PaO2, partial pressure of oxygen in arterial blood; PaCO2, partial
pressure of carbon dioxide in arterial blood; SpO2, pulse oximetry; CCI, Charlson comorbidity index; BMI, body mass index; FFMI, fat-free
mass index; HGS dh, handgrip strength of the dominant hand; HGS ndh, handgrip strength of the non-dominant hand; BDI, baseline
dyspnea index; nZ 57 survivor group; nZ 77 non-survivor; SGRQ, St. George’s Respiratory Questionnaire; nZ 57 survivor group, nZ 79
non-survivor group.
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By the end of the 3 year follow-up period, 83 patients (58%)
had died. In average the survival since baseline in our study
was 767  406 days.” The variables associated with reduced
survival in the univariate analysis (Table 2) with p < 0.20
were included in the multiple Cox proportional hazard
models (Table 3). To avoid colinearity we created two
models, one included the variable Hb and other included
Htc. Results showed that in both models the variables Htc
(HR, 0.96; 95%CI 0.91e0.99; p Z 0.04) and Hb (HR, 0.86;
95%CI 0.76e0.98; p Z 0.02) were selected as predictors of
mortality after three years. Other significant predictors of
mortality were male gender, low PaCO2 and SpO2, higher
dyspnea perception (BDI) and impairment of HS.
The cut-off points to identify the best survival values
were as follows: BDI  1 (sensitivity 90% specificity 70%),
SpO2  73% (sensitivity 97% specificity 87%), Hb  11 g/dl
(sensitivity 95% specificity 85%), Htc  33% (sensitivity 97%
specificity 89%). KaplaneMeier survival curves for the above
variables are presented in Fig. 2.Discussion
In this study, we evaluated the predictors of mortality in
patients with CRF receiving LTOT. Multiple regressionanalysis showed that the main risk factors for mortality
after three years of follow-up were male gender, lower
values of hemoglobin, hematocrit and PaCO2, more intense
hypoxemia and dyspnea sensation.
Hematocrit and hemoglobin were significantly lower in
the non-survivors group and both were predictors of
mortality in the third year of follow-up. The cut-off point
associated with higher mortality in our study was Hb 11 g/
dl (sensitivity 95% specificity 85%) or Htc  33% (sensitivity
97% specificity 89%). These data are consistent with the
results of a study that evaluated 2524 patients with COPD
receiving LTOT13 and showed that the survival rate at three
years was 24% in patients with Htc< 35% and 70% in patients
with Htc > 55%. Martinez et al.16 also showed that the
decrease in Hb was independently associated with higher
mortality (OR Z 1.38, 95%CI Z 1.00e1.89, p Z 0.05).
However, in both studies the cut-off point of Hb/Htc asso-
ciated with higher mortality was not determined.
The levels of Hb in patients with CRF related to chronic
diseases reflect the balance between the stimulation of
erythropoiesis by hypoxia and suppression by inflammation.
In our study, 67% of patients presented COPD and 9% had
ILD, both are well known chronic inflammatory diseases
associated with various systemic manifestations.28 In
contrast with previous teaching, recent studies in COPD
have shown a high prevalence of anemia (15e30%),
particularly in patients with severe diseases, whereas
Table 2 Results of the univariate analysis for mortality
after 3-years of follow-up in patients under LTOT.
All patients
Variable p
Gender (M/F) 0.09
Age (years) 0.09
Smoking (pack-years) 0.90
Hb (g/dl) 0.008
Htc (%) 0.009
Anemia (yes/no) 0.07
FEV1 (% pred) 0.87
PaO2 (mmHg) 0.71
PaCO2 (mmHg) 0.04
SpO2 (%) 0.0008
FFM (kg) 0.29
FFMI (kg/m2) 0.02
HGS dh (kgf) 0.07
SGRQt 0.001
BDI <0.0001
M/F, male/female; Hb, hemoglobin; Htc, hematocrit; FEV1,
forced expiratory volume; % pred., % of predicted; PaO2, arte-
rial oxygen tension; PaCO2, partial pressure of carbon dioxide in
arterial blood; SpO2, pulse oximeter; FFM, fat-free mass; FFMI,
fat-free mass index; HGS dh, handgrip strength of the dominant
hand; SGRQt, St. George’s Respiratory Questionnaire (score
total); BDI, baseline dyspnea index.
474 D.F. Lima et al.polycythemia is relatively rare (6%). The prevalence of
anemia in the present study, according to values described
in the literature (WHO),21 was 17%. The anemia is usually of
the normochromic normocytic type and has detrimental
effects on clinical and economic outcomes.29,30 Although
inadequate levels of Hb could worsen tissue hypoxia and
justify its negative effect on prognosis, it remains to be
determined if the treatment of the anemia will result in
better outcomes in patients with CRF under LTOT.
The severity of hypoxemia as measured by the SpO2 was
associated with mortality both in univariate analysis andTable 3 Prognostic factors for mortality after 3-years of
follow-up in patients under LTOT according to the multiple
mortality model.
Predictors Hazard ratio (95% IC) p value
Gender (M/F) 2.67 (1.15e6.18) 0.02
Age (years) 1.01 (0.98e1.04) 0.57
Hb (g/dl) 0.86 (0.76e0.98) 0.02
PaCO2 (mmHg) 0.96 (0.92e0.99) 0.02
SpO2 (%) 0.93 (0.89e0.97) 0.001
FFMI (kg/m2) 1.14 (0.60e2.17) 0.70
HGS dh (kgf) 0.97 (0.92e1.02) 0.19
BDI 0.87 (0.76e0.99) 0.04
SGRQt (%) 1.02 (1.00e1.04) 0.04
Multiple analysis by Cox model; CI, confidence interval; M/F,
male/female; Hb, hemoglobin; PaCO2, partial pressure of
carbon dioxide in arterial blood; SpO2, pulse oximeter; FFMI,
fat-free mass index; HGS dh, handgrip strength of the dominant
hand; BDI, baseline dyspnea index; SGRQt, Saint George
Respiratory Questionnaire (total score).multiple analysis of Cox and the cut-off point identified for
SpO2  73% presented with good sensitivity and specificity
(sensitivity 97% specificity 87%). This is in agreement with
previous findings of several authors showing that the degree
of hypoxemia is an important prognostic factor in patients
with COPD in use or not of LTOT.7,31 Although hypoxemiamay
be adjusted with oxygen supplementation, utilization for at
least 15 h a day of LTOT is necessary to achieve clinical
outcomes32; however, adherence with LTOT is commonly
less than ideal.3 In general, adherence for LTOT varies
between 45 and 65%.3,33 In our study, adherence to treat-
ment among patients who survived was 61% and 42% among
the non-survivors. However, adherence data are subjective
because they were obtained through the patient’s report.
The perception of dyspnea, assessed by the BDI was
more intense in patients who died during follow-up and the
BDI was associated with mortality in both univariate anal-
ysis and in multiple analysis of Cox. Furthermore, the
domain of the SGRQ impact score, which includes several
questions about the influence of dyspnea on functional
capacity of the patient,34 was higher in patients who died.
The cut-off point for BDI was <1 (sensitivity 90% specificity
70%). This is in agreement with previous finding showing
that BDI  3 was a main predictor of one-year mortality in
COPD patients.5 Oga et al.33 also showed that the BDI was
significantly correlated with survival in patients with
moderate to severe COPD, over five years. Therefore,
baseline dyspnea seems to be a strong predictor of
mortality and an instrument to evaluate this symptom
should be included in the management of these patients.
The literature shows controversial results on PaCO2 and
survival of patients using LTOT. In our study, the increase in
PaCO2 was associated with decreased mortality after three
years of follow-up. According to our results, Dubois et al.7
evaluated 270 patients with COPD receiving LTOT and the
risk of mortality was lower in hypercapnic patients
(HR Z 0.86). Another study assessed patients receiving
LTOT and showed that chronic hypercapnia was an inde-
pendent factor for favorable prognosis in patients with
tuberculosis and was not a factor for either favorable or
poor prognosis in patients with COPD once they started
receiving LTOT.8 In contrast, Foucher et al.9 analyzed the
survival in 252 patients with COPD using LTOT and identified
the hypercapnia as negative prognostic factor.
The risk of death in menwas two times higher compared to
women in our study, according to Miyamoto et al.35 who
evaluated 9759 patients with CRF and found higher survival in
women regardless of pathology. Franklin et al.36 studied 5689
patients with COPD in the use of LTOT and survival was also
greater in women than in men (77% versus 69%). In contrast to
our result, Machado et al.14 studied the gender differences in
COPD patients in use of LTOT and, in multivariate analysis,
found that women had a significantly higher risk of death
compared tomen(HRZ1.54, 95%CIZ1.15e2.07,pZ0.004).
The present study is limited by a relative small number
of patients. For future investigations, larger study pop-
ulations are needed. This would allow investigating
whether anemia is related to the primary disease process
per se or to secondary systemic manifestations such as
weight loss, loss of lean tissue mass, hypoxia, or systemic
inflammation. In addition, no intervention to correct
anemia was undertaken in the present study.
Figure 2 KaplaneMeier survival curves of the study population. A e Survival curves for patients with SpO2  73% versus those
with SpO2 > 73% (p < 0.0001). B e Survival curves for patients with BDI  1 versus those with BDI > 1 (p < 0.0001). C e Survival
curves for patients with Hb  11 g/dl versus those with Hb > 11 g/dl (p Z 0.02). D e Survival curves for patients with Htc  33%
versus those with Htc > 33% (p Z 0.03).
Predictors of mortality in LTOT 475In conclusion, our study shows that anemia is a poten-
tially modifiable predictor of mortality in patients with
chronic respiratory failure under LTOT treatment.
However, the effects of raising hemoglobin on mortality
remains undetermined, which justifies further studies to
prospectively evaluate the effect of anemia correction on
the prognosis of such patients.
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